Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 01/20/04 → 11/5/05 |
Funding
- Merck and Company: $4,873.00
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Rofecoxib in Decreasing the Risk of Prostate Cancer (ViP Study)
- Adler, Howard (PI)
- Langenback, Edward (CoPI)
Project: Research